What is the safest first step in managing a patient with severe anxiety (10/10) and progressive vision loss who is taking temazepam, diazepam, hydroxyzine, trazodone, and vortioxetine?

Immediate Benzodiazepine Deprescribing with Urgent Ophthalmology Evaluation

The safest first step is to urgently refer this patient to ophthalmology for same-day evaluation of progressive vision loss while simultaneously initiating a gradual taper of the dual benzodiazepine regimen (temazepam and diazepam), as this polypharmacy represents a high-risk situation with potential medication-induced angle-closure glaucoma.

Critical Safety Concerns

This patient presents with two emergent issues requiring immediate action:

Vision Loss Emergency

Progressive vision loss in a patient on multiple psychotropic medications—particularly benzodiazepines, trazodone, and hydroxyzine—raises serious concern for medication-induced angle-closure glaucoma. Antidepressants and antianxiety agents can precipitate bilateral angle closure glaucoma in susceptible patients, leading to irreversible vision loss if not promptly treated 1. Multiple psychotropic agents cause mydriasis and can promote angle closure, with TCAs, typical antipsychotics, and SSRIs all implicated 2. Same-day ophthalmology evaluation is non-negotiable to rule out acute angle-closure glaucoma, which constitutes an ophthalmologic emergency.

Dangerous Benzodiazepine Polypharmacy

The concurrent use of temazepam and diazepam represents high-risk polypharmacy that violates current consensus guidelines. Benzodiazepines should only be used short-term and are associated with cognitive impairment, falls, fractures, reduced mobility, and addiction—particularly dangerous in any patient with vision impairment 3. The FDA explicitly warns that abrupt discontinuation can precipitate life-threatening withdrawal reactions 4.

Immediate Action Algorithm

Step 1: Emergency Ophthalmology Referral (Same Day)

• Arrange immediate evaluation for angle-closure glaucoma
• Document all current medications for ophthalmologist
• Check intraocular pressures and gonioscopy
• If angle-closure confirmed, this becomes the primary driver of medication changes

Step 2: Initiate Benzodiazepine Consolidation and Taper

Do not abruptly discontinue—this risks life-threatening withdrawal including seizures 4.

• Week 1-2: Convert to single benzodiazepine (diazepam preferred for its longer half-life facilitating smoother taper)
• Calculate total diazepam equivalents (temazepam 15mg ≈ diazepam 10mg)
• Week 3 onward: Reduce by 25% every 1-2 weeks, though slower tapers extending over many weeks are often necessary to minimize withdrawal risk 3
• Monitor closely for rebound anxiety, insomnia, tremor, or seizure activity

Step 3: Address Anxiety with Safer Alternatives

Given the 10/10 anxiety severity, substitution therapy is essential during benzodiazepine taper:

First-line option: The patient is already on vortioxetine (an SSRI/modulator). Optimize this dose first, as SSRIs are first-line for generalized anxiety disorder in older adults 5.

Second-line additions if needed:

• Pregabalin or gabapentin (evidence-based for anxiety, safer profile than benzodiazepines) 5
• Consider buspirone if avoiding sexual side effects is priority 5

Step 4: Evaluate Other Medications Contributing to Risk

Trazodone concerns:

• Can cause visual hallucinations 6
• Prolongs QT interval and causes orthostatic hypotension 7
• Combined with multiple CNS depressants increases fall risk
• Consider tapering if not providing clear benefit

Hydroxyzine:

• Has anticholinergic properties that can worsen angle-closure risk
• Recommended for caution in older adults 5
• Consider discontinuation once benzodiazepine taper progresses

Critical Pitfalls to Avoid

1. Never abruptly stop benzodiazepines—the FDA explicitly warns this can be life-threatening, causing acute withdrawal reactions 4. Gradual taper over weeks to months is mandatory.

2. Do not dismiss vision loss as anxiety-related until organic causes are excluded. Medication-induced angle-closure glaucoma can cause permanent blindness within hours to days 1.

3. Avoid adding more medications before addressing the dangerous polypharmacy. This patient is on five psychotropic agents—deprescribing is the priority 3.

4. Do not continue dual benzodiazepines even during taper. Consolidate to single agent immediately to reduce compounded risks 3.

5. Monitor for protracted withdrawal syndrome—benzodiazepine withdrawal can last weeks to over 12 months in some patients 4.

Monitoring Parameters

• Daily initially: Vision changes, anxiety severity, withdrawal symptoms (tremor, sweating, agitation, seizures)
• Weekly during taper: Vital signs, fall assessment, cognitive function
• Ongoing: Intraocular pressure if angle-closure diagnosed, medication adherence to taper schedule

The combination of progressive vision loss with high-risk benzodiazepine polypharmacy creates a medical emergency requiring immediate ophthalmologic intervention and systematic medication rationalization. The 10/10 anxiety must be managed, but not at the expense of vision or life-threatening withdrawal—hence the gradual, supervised approach with safer alternative anxiolytics 3, 5.